Ultragenyx Pharmaceutical | RARE - Cost Of Sales

Stock Price
24.65
Daily Change
0.86 3.62%
Monthly
1.86%
Yearly
-45.65%
Q1 Forecast
23.33

Ultragenyx Pharmaceutical reported $27.99M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Agios Pharmaceuticals USD 1.68M 22K Sep/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Insmed USD 30.9M 1.56M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
Kyowa Hakko Kirin JPY 28.2B 9.08B Sep/2025
MacroGenics USD 44.3M 5.4M Sep/2025
Moderna USD 207M 88M Sep/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
PTC Therapeutics USD 23.32M 7.83M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025